LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Royalty Pharma PLC (Class A)

Gesloten

SectorGezondheidszorg

36.08 -2.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

35.78

Max

36.35

Belangrijke statistieken

By Trading Economics

Inkomsten

-403M

30M

Verkoop

10M

579M

K/W

Sectorgemiddelde

15.712

35.733

EPS

1.06

Dividendrendement

2.41

Winstmarge

5.215

EBITDA

-375M

159M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+20.88% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.41%

3.13%

Volgende dividenddatum

10 sep 2025

Volgende Ex Dividend datum

14 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-315M

21B

Vorige openingsprijs

38.12

Vorige sluitingsprijs

36.08

Nieuwssentiment

By Acuity

50%

50%

176 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Royalty Pharma PLC (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jun 2025, 10:49 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

Peer Vergelijking

Prijswijziging

Royalty Pharma PLC (Class A) Prognose

Koersdoel

By TipRanks

20.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 43.6 USD  20.88%

Hoogste 55 USD

Laagste 37 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Royalty Pharma PLC (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Technische score

By Trading Central

33 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

176 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat